PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

aprepitant Side Effects

The reactions most often reported to the FDA for aprepitant (also sold as Emend), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

17,740
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2004 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of aprepitant come from 17,740 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 17,740 reports to the FDA Adverse Event Reporting System (FAERS) for aprepitant (Emend): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

17,740

Reports Mentioning Death

2,942

16.6% of reports — not proof the medicine caused the death

Hospitalizations

9,758

55.0% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

NAUSEA
2,145
FATIGUE
1,769
PYREXIA
1,589
DIARRHOEA
1,542
DYSPNOEA
1,508
VOMITING
1,474
ALOPECIA
1,274
RASH
1,210
HYPERSENSITIVITY
1,133
FEBRILE NEUTROPENIA
1,043
DECREASED APPETITE
1,038
PRURITUS
1,020
STOMATITIS
992
INFUSION RELATED REACTION
972
PAIN
955
CONFUSIONAL STATE
909
ASTHENIA
876
INFECTION
874
GASTROINTESTINAL DISORDER
852

Who Reports Side Effects

Gender Distribution

Female 10,115 (62%)
Male 5,983 (37%)
Unknown 121

Age Distribution

0-17 683 (5%)
18-44 2,702 (19%)
45-64 6,016 (43%)
65-74 3,442 (25%)
75+ 1,120 (8%)

Reporting Trend by Year

2004 2025

Reactions in Death Reports

Top reactions reported in 2,942 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 529
FATIGUE 515
VOMITING 493
DIARRHOEA 476
PYREXIA 461
GENERAL PHYSICAL HEALTH DETERIORATION 447
HAND DEFORMITY 416
FOLLICULITIS 409
GLOSSODYNIA 404
NAUSEA 403
IMPAIRED HEALING 401
HYPERSENSITIVITY 396
DECREASED APPETITE 394
STOMATITIS 394
HELICOBACTER INFECTION 392
CONFUSIONAL STATE 386
JOINT SWELLING 383
RASH 380
INFECTION 377

Reactions in Hospitalization Reports

Top reactions in 9,758 reports where hospitalization was an outcome.

Reaction Reports
PYREXIA 1,317
NAUSEA 1,177
FATIGUE 1,163
DIARRHOEA 1,090
VOMITING 1,050
DYSPNOEA 1,004
RASH 920
FEBRILE NEUTROPENIA 910
STOMATITIS 814
HYPERSENSITIVITY 807
GENERAL PHYSICAL HEALTH DETERIORATION 787
PRURITUS 778
CONFUSIONAL STATE 776
ALOPECIA 767
INFUSION RELATED REACTION 761
GASTROINTESTINAL DISORDER 757
DECREASED APPETITE 749
INFECTION 747
PAIN 731

Compare aprepitant vs alosetron →

What the FAERS Data Reveals About aprepitant Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 17,740 voluntary reports linked to aprepitant and its brand equivalents (Emend), spanning 2004 through 2025. Of those, 2,942 (16.6%) listed death as an outcome and 9,758 (55.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 62% were female and 37% male; age distribution skews toward 45-64, with 6,016 reports in that bracket. The single most reported reaction is nausea with 2,145 submissions, followed by fatigue and pyrexia.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.